Evaluating the Potential of Cubosomal Nanoparticles for Oral Delivery of Amphotericin B in Treating Fungal Infection

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2014 Jan 15

PMID 24421641

Citations 21

Authors

Zhiwen Yang

Meiwan Chen

Muhua Yang

Jian Chen

Weijun Fang

Ping Xu

Affiliations

Soon will be listed here.

Abstract

The oral administration of amphotericin B (AmB) has a major drawback of poor bioavailability. The aim of this study was to investigate the potential of glyceryl monoolein (GMO) cubosomes as lipid nanocarriers to improve the oral efficacy of AmB. Antifungal efficacy was determined in vivo in rats after oral administration, to investigate its therapeutic use. The human colon adenocarcinoma cell line (Caco-2) was used in vitro to evaluate transport across a model of the intestinal barrier. In vivo antifungal results showed that AmB, loaded in GMO cubosomes, could significantly enhance oral efficacy, compared against Fungizone, and that during a 2 day course of dosage 10 mg/kg the drug reached effective therapeutic concentrations in renal tissue for treating fungal infections. In the Caco-2 transport studies, GMO cubosomes resulted in a significantly larger amount of AmB being transported into Caco-2 cells, via both clathrin- and caveolae-mediated endocytosis, but not macropinocytosis. These results suggest that GMO cubosomes, as lipid nanovectors, could facilitate the oral delivery of AmB.

Citing Articles

Oral Drug Delivery via Intestinal Lymphatic Transport Utilizing Lipid-Based Lyotropic Liquid Crystals.

Dinh L, Yan B Liquids (Basel). 2024; 3(4):456-468.

PMID: 38711572 PMC: 11073766. DOI: 10.3390/liquids3040029.

Recent Advances in the Development of Liquid Crystalline Nanoparticles as Drug Delivery Systems.

Leu J, Teoh J, Ling A, Chong J, Loo Y, Azmi I Pharmaceutics. 2023; 15(5).

PMID: 37242663 PMC: 10224018. DOI: 10.3390/pharmaceutics15051421.

Liposomal Amphotericin B for Treatment of Leishmaniasis: From the Identification of Critical Physicochemical Attributes to the Design of Effective Topical and Oral Formulations.

Frezard F, Aguiar M, Ferreira L, Ramos G, Santos T, Borges G Pharmaceutics. 2023; 15(1).

PMID: 36678729 PMC: 9864876. DOI: 10.3390/pharmaceutics15010099.

Potential lipid-based strategies of amphotericin B designed for oral administration in clinical application.

Zhong X, Yang J, Liu H, Yang Z, Luo P Drug Deliv. 2023; 30(1):2161671.

PMID: 36601799 PMC: 9828648. DOI: 10.1080/10717544.2022.2161671.

Orally Administered Amphotericin B Nanoformulations: Physical Properties of Nanoparticle Carriers on Bioavailability and Clinical Relevance.

Fairuz S, Nair R, Billa N Pharmaceutics. 2022; 14(9).

PMID: 36145572 PMC: 9505005. DOI: 10.3390/pharmaceutics14091823.

References

Li N, Li X, Zhou Y, Li W, Zhao Y, Ma S . The use of polyion complex micelles to enhance the oral delivery of salmon calcitonin and transport mechanism across the intestinal epithelial barrier. Biomaterials. 2012; 33(34):8881-92. DOI: 10.1016/j.biomaterials.2012.08.047. View

Vertzoni M, Markopoulos C, Symillides M, Goumas C, Imanidis G, Reppas C . Luminal lipid phases after administration of a triglyceride solution of danazol in the fed state and their contribution to the flux of danazol across Caco-2 cell monolayers. Mol Pharm. 2012; 9(5):1189-98. DOI: 10.1021/mp200479f. View

Wasan E, Bartlett K, Gershkovich P, Sivak O, Banno B, Wong Z . Development and characterization of oral lipid-based amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans. Int J Pharm. 2009; 372(1-2):76-84. DOI: 10.1016/j.ijpharm.2009.01.003. View

Roger E, Lagarce F, Garcion E, Benoit J . Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis. J Control Release. 2009; 140(2):174-81. DOI: 10.1016/j.jconrel.2009.08.010. View

Risovic V, Sachs-Barrable K, Boyd M, Wasan K . Potential mechanisms by which Peceol increases the gastrointestinal absorption of amphotericin B. Drug Dev Ind Pharm. 2004; 30(7):767-74. DOI: 10.1081/ddc-120039793. View

Roger E, Kalscheuer S, Kirtane A, Guru B, Grill A, Whittum-Hudson J . Folic acid functionalized nanoparticles for enhanced oral drug delivery. Mol Pharm. 2012; 9(7):2103-10. PMC: 3461242. DOI: 10.1021/mp2005388. View

Meng S, Wu B, Singh R, Yin T, Morrow J, Zhang S . SULT1A3-mediated regiospecific 7-O-sulfation of flavonoids in Caco-2 cells can be explained by the relevant molecular docking studies. Mol Pharm. 2012; 9(4):862-73. PMC: 3404749. DOI: 10.1021/mp200400s. View

Gershkovich P, Wasan E, Lin M, Sivak O, Leon C, Clement J . Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation. J Antimicrob Chemother. 2009; 64(1):101-8. DOI: 10.1093/jac/dkp140. View

Damge C, Reis C, Maincent P . Nanoparticle strategies for the oral delivery of insulin. Expert Opin Drug Deliv. 2007; 5(1):45-68. DOI: 10.1517/17425247.5.1.45. View

10.

Mo R, Jin X, Li N, Ju C, Sun M, Zhang C . The mechanism of enhancement on oral absorption of paclitaxel by N-octyl-O-sulfate chitosan micelles. Biomaterials. 2011; 32(20):4609-20. DOI: 10.1016/j.biomaterials.2011.03.005. View

11.

Verma R, Pandya S, Misra A . Loading and release of amphotericin-B from biodegradable poly(lactic-co-glycolic acid) nanoparticles. J Biomed Nanotechnol. 2011; 7(1):118-20. DOI: 10.1166/jbn.2011.1230. View

12.

Fatouros D, Bergenstahl B, Mullertz A . Morphological observations on a lipid-based drug delivery system during in vitro digestion. Eur J Pharm Sci. 2007; 31(2):85-94. DOI: 10.1016/j.ejps.2007.02.009. View

13.

Robbie G, Chiou W . Elucidation of human amphotericin B pharmacokinetics: identification of a new potential factor affecting interspecies pharmacokinetic scaling. Pharm Res. 1998; 15(10):1630-6. DOI: 10.1023/a:1011923704731. View

14.

Incecayir T, Tsume Y, Amidon G . Comparison of the permeability of metoprolol and labetalol in rat, mouse, and Caco-2 cells: use as a reference standard for BCS classification. Mol Pharm. 2013; 10(3):958-66. PMC: 3605724. DOI: 10.1021/mp300410n. View

15.

Benincasa M, Pacor S, Wu W, Prato M, Bianco A, Gennaro R . Antifungal activity of amphotericin B conjugated to carbon nanotubes. ACS Nano. 2010; 5(1):199-208. DOI: 10.1021/nn1023522. View

16.

Ibrahim F, Gershkovich P, Sivak O, Wasan E, Bartlett K, Wasan K . Efficacy and toxicity of a tropically stable lipid-based formulation of amphotericin B (iCo-010) in a rat model of invasive candidiasis. Int J Pharm. 2012; 436(1-2):318-23. DOI: 10.1016/j.ijpharm.2012.06.062. View

17.

Hosmer J, Steiner A, Lopes L . Lamellar liquid crystalline phases for cutaneous delivery of Paclitaxel: impact of the monoglyceride. Pharm Res. 2012; 30(3):694-706. DOI: 10.1007/s11095-012-0908-0. View

18.

Kossena G, Charman W, Wilson C, OMahony B, Lindsay B, Hempenstall J . Low dose lipid formulations: effects on gastric emptying and biliary secretion. Pharm Res. 2007; 24(11):2084-96. DOI: 10.1007/s11095-007-9363-8. View

19.

Zhen G, Hinton T, Muir B, Shi S, Tizard M, McLean K . Glycerol monooleate-based nanocarriers for siRNA delivery in vitro. Mol Pharm. 2012; 9(9):2450-7. DOI: 10.1021/mp200662f. View

20.

Patel P, Patravale V . AmbiOnp: solid lipid nanoparticles of amphotericin B for oral administration. J Biomed Nanotechnol. 2011; 7(5):632-9. DOI: 10.1166/jbn.2011.1332. View